{"filing":{"accession_number":"0001437749-26-020080","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"crvo20260610_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926020080/crvo20260610_8k.htm"},"events":[{"id":5720,"run_id":5012,"accession_number":"0001437749-26-020080","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"CervoMed entered into a securities purchase agreement for a private placement of 3,360,377 units comprising common stock (or pre-funded warrants) and Series B and C warrants, generating approximately $10.5 million in gross proceeds with potential additional $21.7 million upon warrant exercise. The unregistered securities are subject to resale restrictions, with significant insider participation from the CEO, Chair, and Director. Proceeds will be used for R\u0026D and operations.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5719,"accession_number":"0001437749-26-020080","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed entered into a securities purchase agreement for a private placement of 3,360,377 units comprising common stock (or pre-funded warrants) and Series B and C warrants, generating approximately $10.5 million in gross proceeds with potential additional $21.7 million upon warrant exercise. This is a classic dilutive equity issuance under Item 1.01, with significant dilution potential and insider participation (CEO, Chair, and Director involvement in 1,369,426 units). The company explicitly states it will use proceeds for R\u0026D and operations, and the registration statement obligation confirms the securities are unregistered and subject to resale restrictions typical of private placements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5720,"accession_number":"0001437749-26-020080","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly addresses unregistered sales of equity securities. Although the specific details are incorporated by reference from Item 1.01, the filing of Item 3.02 itself signals a dilutive equity issuance. Such transactions are material to investors as they affect ownership dilution and capital structure, particularly at smaller-cap issuers like CervoMed.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5721,"run_id":5012,"accession_number":"0001437749-26-020080","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"CervoMed disclosed entry into a Purchase Agreement and provided business updates via press release on June 10, 2026, including Strategic Pipeline Priorities. The specific terms and financial impact of the Purchase Agreement are not detailed in the filing excerpt, preventing confident classification as a more specific event type such as M\u0026A activity.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5721,"accession_number":"0001437749-26-020080","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses entry into a \"Purchase Agreement\" and provides \"business updates\" via press release on June 10, 2026, but the actual terms, counterparty, and financial impact are not detailed in this Item 7.01 excerpt. The reference to a Purchase Agreement suggests potential M\u0026A activity or a material transaction, but without specifics on whether this is an acquisition, disposition, or other material contract, the event cannot be confidently classified as ma_activity. The Item 7.01 safe-harbor language and incorporation of Exhibit 99.1 indicate this is a Regulation FD disclosure of material information, warranting classification as a material event that does not fit a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5722,"accession_number":"0001437749-26-020080","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The Item 8.01 disclosure incorporates by reference a \"Strategic Pipeline Priorities\" section from a June 10, 2026 press release. While the specific content is not provided in the filing excerpt, pipeline strategy disclosures for a biopharmaceutical company (CervoMed) typically address material development plans and priorities that would affect investor assessment of future prospects. Without access to the actual press release content, this is classified as other_material rather than a more specific event type, though it could potentially relate to material business developments or strategic shifts.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5719,"accession_number":"0001437749-26-020080","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed entered into a securities purchase agreement for a private placement of 3,360,377 units comprising common stock (or pre-funded warrants) and Series B and C warrants, generating approximately $10.5 million in gross proceeds with potential additional $21.7 million upon warrant exercise. This is a classic dilutive equity issuance under Item 1.01, with significant dilution potential and insider participation (CEO, Chair, and Director involvement in 1,369,426 units). The company explicitly states it will use proceeds for R\u0026D and operations, and the registration statement obligation confirms the securities are unregistered and subject to resale restrictions typical of private placements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-10"},{"id":5720,"accession_number":"0001437749-26-020080","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 explicitly addresses unregistered sales of equity securities. Although the specific details are incorporated by reference from Item 1.01, the filing of Item 3.02 itself signals a dilutive equity issuance. Such transactions are material to investors as they affect ownership dilution and capital structure, particularly at smaller-cap issuers like CervoMed.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-10"},{"id":5721,"accession_number":"0001437749-26-020080","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses entry into a \"Purchase Agreement\" and provides \"business updates\" via press release on June 10, 2026, but the actual terms, counterparty, and financial impact are not detailed in this Item 7.01 excerpt. The reference to a Purchase Agreement suggests potential M\u0026A activity or a material transaction, but without specifics on whether this is an acquisition, disposition, or other material contract, the event cannot be confidently classified as ma_activity. The Item 7.01 safe-harbor language and incorporation of Exhibit 99.1 indicate this is a Regulation FD disclosure of material information, warranting classification as a material event that does not fit a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-10"},{"id":5722,"accession_number":"0001437749-26-020080","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The Item 8.01 disclosure incorporates by reference a \"Strategic Pipeline Priorities\" section from a June 10, 2026 press release. While the specific content is not provided in the filing excerpt, pipeline strategy disclosures for a biopharmaceutical company (CervoMed) typically address material development plans and priorities that would affect investor assessment of future prospects. Without access to the actual press release content, this is classified as other_material rather than a more specific event type, though it could potentially relate to material business developments or strategic shifts.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T11:42:19.595248+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-10"}]}